Soleno Therapeutics, Inc.
SLNO
$33.39
-$0.37-1.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.81% | 76.83% | 436.92% | 563.11% | 685.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.87% | 32.12% | 219.70% | 281.03% | 376.93% |
| Operating Income | 108.11% | 39.14% | -172.03% | -281.03% | -376.93% |
| Income Before Tax | 111.88% | 40.19% | -176.84% | -280.98% | -351.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 111.88% | 40.19% | -176.84% | -280.98% | -351.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.88% | 40.19% | -176.84% | -280.98% | -351.04% |
| EBIT | 108.11% | 39.14% | -172.03% | -281.03% | -376.93% |
| EBITDA | 109.30% | 39.74% | -177.03% | -291.60% | -396.95% |
| EPS Basic | 105.97% | 44.85% | -70.28% | -72.18% | -43.20% |
| Normalized Basic EPS | 108.99% | 46.30% | -78.34% | -77.89% | -49.62% |
| EPS Diluted | 105.14% | 44.23% | -70.41% | -72.31% | -43.31% |
| Normalized Diluted EPS | 108.22% | 45.85% | -78.34% | -77.89% | -49.62% |
| Average Basic Shares Outstanding | 26.47% | 28.28% | 51.15% | 84.43% | 144.33% |
| Average Diluted Shares Outstanding | 28.18% | 29.34% | 51.15% | 84.43% | 144.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |